Bristol-Myers-Squibb announced that Amgen will acquire Celgene’s Otezla business for $13.4 billion in a cash transaction. Bristol-Myers now expects to complete the pending merger with Celgene by the end of 2019. For More:
What's the reason for Celgene going down even after beating the estimates and lifting 2018 outlook? Any thoughts? https://news.alphastreet.com/celgene-celg-stock-q3-2018-earnings/
anonymous
Thread
bristol-myers squibb
celgene
earnings
mark alles
merck
novartis
otezla
outlook
pharma
revlimid
http://alph.st/ba1df6ff Higher sales of Revlimid and Otezla help Celgene to report better than expected sales figure. Will the two (Impact and Juno) multi-billion dollar acquisitions help the struggling Celgene in 2018 and beyond?
anonymous
Thread
cancer
cancer treatment
celgene
earnings
juno therapeutics
otezla
outlook
revlimid
tax reform